AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$CSTL

MAETZOLD DEREK J sold $189K of CSTL (indirect holdings)

MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 5,916 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at $31.91 ($0.19M total) across 2 trades on 2026-10-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAETZOLD DEREK J
Published Oct 21, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Bearish
medium confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLBearishLow
01

Why it matters

The disclosed sale may prompt short‑term price weakness, but long‑term impact depends on company performance.

02

Market read

A modest insider sell by the CEO, likely to cause short‑term bearish sentiment.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$CSTLBearishMedium confidence
Context

CEO Derek Maetzold sold 5,916 shares (~$188.8k) via a 10b5‑1 plan, reducing his stake to 4,114 shares.

Expected impact

likely downward pressure as the market prices the insider sell

Evidence & confidence

A senior executive sold a material amount of shares; such sales often trigger short‑term sell‑offs.

Market effects

Sector

Minimal impact on the broader biotech sector; the sale is company‑specific.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to fundamentals.

Key entities

  • Individual
    Derek J. Maetzold

    President & Chief Executive Officer of Castle Biosciences

  • Company
    Castle Biosciences Inc.

    Biotech firm developing diagnostic technologies

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

$CSTLMed

DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

Castle Biosciences presented data on DecisionDx-Melanoma at SDPA and Dermato-Onco2026, showing the test can identify higher-risk patients with thin melanomas and provide individualized five-year recurrence-risk estimates. The studies suggest the test refines risk assessment beyond AJCC staging, aiding personalized care. According to the company, the test has been ordered over 260,000 times and is supported by extensive research.

prnewswire.com
$CSTLMed

Castle Bio (CSTL) Q3 2026 Earnings Call Transcript

Castle Bio (CSTL) reported Q3 2026 revenue of $102.9M, up 24% YoY, driven by 47% growth in TissueCypher test volume. Net cash from operations was $19.7M, with $278M in cash and equivalents. The company raised full-year revenue guidance to $385M-$395M, up from $365M-$375M. DecisionDx-Melanoma saw 5% YoY growth, while TissueCypher is expected to grow 50%-52% for the year.

finance.yahoo.com
$CSTLHigh

Castle Biosciences Reports Third Quarter 2026 Results

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Third Quarter 2026 Results Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 m

SEC EDGAR 8-K
$CSTLHighAI 8/10

Castle Biosciences Reports Third Quarter 2026 Results

Castle Biosciences reported Q3 2026 revenue of $102.9M, up 24% YoY. TissueCypher test volume rose 47% YoY. The company raised full-year 2026 revenue guidance to $385-395M. Q3 net loss was $4.1M, with Adjusted EBITDA of $12.7M. The company presented new data on its DecisionDx-Melanoma test at EADV Congress 2026.

prnewswire.com
$CSTLMed

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Castle Biosciences presented data at EADV 2026 showing DecisionDx-Melanoma's ability to predict low SLN positivity and high recurrence risk in melanoma patients. The study involved 2,799 patients across 29 U.S. centers, with low-risk patients avoiding SLNB showing 99.6% five-year RFS. The test also stratified recurrence risk in early-stage, transected melanomas, supporting tailored surveillance. Castle Biosciences is a Nasdaq-listed company (CSTL).

prnewswire.com